Results 161 to 170 of about 3,081 (193)
Some of the next articles are maybe not open access.
Blood
Abstract Background: Targeted regimens incorporating selective inhibitor of BCL-2 like venetoclax and Bruton Tyrosine Kinase inhibitors (BTKi) like ibrutinib have redefined first-line therapy for B-cell chronic lymphocytic leukemia (CLL), demonstrating high rates of ...
Ansy Patel +5 more
openaire +1 more source
Abstract Background: Targeted regimens incorporating selective inhibitor of BCL-2 like venetoclax and Bruton Tyrosine Kinase inhibitors (BTKi) like ibrutinib have redefined first-line therapy for B-cell chronic lymphocytic leukemia (CLL), demonstrating high rates of ...
Ansy Patel +5 more
openaire +1 more source
Polypharmazie - Wechselwirkungen der BTKi
Oncology Research and Treatment, 2022openaire +1 more source
BTKi, venetoclax, obinutuzumab: what is the ideal combination?
memo - Magazine of European Medical Oncology, 2021openaire +1 more source
[Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia].
Zhongguo shi yan xue ye xue za zhiTo analyze the immune reconstitution after BTKi treatment in patients with chronic lymphocytic leukemia (CLL).The clinical and laboratorial data of 59 CLL patients admitted from January 2017 to March 2022 in Fujian Medical University Union Hospital were collected and analyzed retrospectively.The median age of 59 CLL patients was 60.5(36-78).
Yuan-Li, Wang +7 more
openaire +1 more source
Hub Genes Identification in Btki Resistant Mantle Cell Lymphoma
Blood, 2022Shuozi Liu +4 more
openaire +1 more source
EXABS-124-CLL Extended Abstract: New BTKi
Clinical Lymphoma Myeloma and Leukemia, 2022openaire +1 more source
Paul J. Hampel, Sameer A. Parikh
openaire +2 more sources
HARNESSING BTKI THERAPY BY CDK4/6I CONTROL OF T CELL SURVEILLANCE
Hematological Oncology, 2023S. Chen‐Kiang +5 more
openaire +1 more source
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI)
Hematological Oncology, 2023L. Dai +11 more
openaire +1 more source